Custom synthesis | Naphthyridine | Pyrimidine | Indoline |
Peptides

Bremelanotide 189691-06-3

Bremelanotide 189691-06-3

Bremelanotide, formerly known as PT-141, is a peptide drug which is (or has) been under development by Palatin Technologies as a treatment for female sexual dysfunction (FSD), hemorrhagic shock, and reperfusion injury. Bremelanotide was originally tested for intranasal administration in treating FSD but this application was temporarily discontinued in 2008 after concerns were raised over increased blood pressure seen with bremelanotide administration in some patients.

GMP for Bremelanotide 189691-06-3 is not available.
 
Disclaimer:Those products (Bremelanotide 189691-06-3) are for lab analytical & research purposes only.